What is the appropriate dosage of trimethoprim‑sulfamethoxazole for a 17‑year‑old female weighing 52.7 kg with an uncomplicated urinary tract infection?

Dosage of TMP-SMX for 17-Year-Old Female with UTI

For a 17-year-old female weighing 52.7 kg with an uncomplicated UTI, prescribe trimethoprim-sulfamethoxazole 160/800 mg (one double-strength tablet) twice daily for 3 days 1.

Key Dosing Information

The standard adult dosing applies to this patient since she is 17 years old and weighs 52.7 kg:

• Dose: 160 mg trimethoprim/800 mg sulfamethoxazole (1 DS tablet)
• Frequency: Twice daily (every 12 hours)
• Duration: 3 days for uncomplicated cystitis 1

This represents the evidence-based first-line regimen for acute uncomplicated cystitis when local resistance rates are below 20% 1.

Critical Caveat: Local Resistance Patterns

You must verify that local E. coli resistance to TMP-SMX is <20% before prescribing this empirically 1. The IDSA/ESMID guidelines establish this 20% threshold as the cutoff beyond which TMP-SMX should not be used for empirical treatment 1. If resistance exceeds 20% in your area, alternative first-line agents include:

• Nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days 1
• Fosfomycin trometamol 3 g single dose 1

Duration Considerations

While the FDA label 2 states 10-14 days for UTI treatment, clinical trial evidence strongly supports 3-day therapy for uncomplicated cystitis 1. Multiple high-quality studies demonstrate that 3-day regimens achieve:

• 90-100% early clinical cure rates 1
• 85-90% long-term cure rates 1
• Significantly fewer adverse effects (8.7% vs 38% with 7-day therapy) 1

The Cochrane review 3 found that while 5-10 day therapy achieves slightly higher bacteriological cure rates, 3-day therapy produces equivalent symptomatic cure with better tolerability.

Alternative Duration for Specific Scenarios

Use 14 days of TMP-SMX 160/800 mg twice daily if:

• Upper tract involvement (pyelonephritis) is suspected 1
• Patient is male (to cover possible prostatitis) 4
• Complicated UTI factors are present 4

For uncomplicated pyelonephritis specifically, the 2024 EAU guidelines 4 recommend 14 days of TMP-SMX at the same dose (160/800 mg twice daily).

Common Pitfalls to Avoid

1. Don't use TMP-SMX if the patient received it within the past 6 weeks - this significantly increases resistance risk (adjusted OR 3.8) 1

2. Don't prescribe empirically if local resistance data are unavailable - resistance correlates directly with treatment failure 1

3. Don't extend to 10 days for simple cystitis - this increases adverse effects (28% vs 5% with single-dose) 5 without improving symptomatic outcomes 3

4. Verify the patient has no complicating factors - diabetes with urological complications, immunosuppression, pregnancy, or anatomical abnormalities would change management 4, 1

Efficacy Data

When susceptibility is confirmed, TMP-SMX demonstrates excellent outcomes:

• Clinical cure: 90-100% at early follow-up 1
• Bacteriological cure: 91-93% 1
• However, resistance drops efficacy dramatically (84% cure with susceptible organisms vs 41% with resistant strains, P<0.001) 1